AZYO - Surgalign launches new device for bone formation

Surgalign ([[SRGA]] +1.5%) commences the commercial launch and the completion of the first surgery of ViBone Moldable, the newest orthobiologics solution of Surgalign’s bone graft portfolio to support spinal fusion, which currently include ViBone and other advanced bone graft solutions, in the US.The first implantation was completed by Dr. Adam Crowl, at OrthoVirgina in Midlothian, VA.ViBone Moldable, provided by Aziyo Biologics ([[AZYO]] +0.8%) has developed a proprietary processing methodology for human tissue that creates next-generation viable cell bone matrix ((VBM)) allografts that contain the scaffold, growth factors and cells required for regeneration of bone. The design is to protect native elements of bone, including growth factors and osteoprogenitor cells that are known to be biologically active and critical for successful bone formation.

For further details see:

Surgalign launches new device for bone formation